阿斯利康称未发现接种疫苗增加血栓风险证据
阿斯利康(AZN.US)表示,其与英国牛津大学共同研发的新型冠状病毒疫苗,在仔细审查欧盟及英国超过1,700万名已接种该疫苗人士的所有安全数据後,於任何年龄层、性别、国家或地区,都未发现证据显示接种会增加肺栓塞、深静脉栓塞,或导致血小板减少的风险。
公司指,根据截至3月8日收到的病例,整个欧盟及英国已报告15宗深静脉栓塞和22宗肺栓塞个案,在此等人口规模下自然发生的情况较预期低很多,而且与其他获批的新冠疫苗相似。
欧洲多国因应有民众注射阿斯利康疫苗後出现血栓情况,早前宣布暂时停用该款疫苗作为预防措施。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.